{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T11:46:55Z","timestamp":1791978415099,"version":"4.4.0"},"reference-count":67,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82204472"],"award-info":[{"award-number":["82204472"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100019018","name":"Chinese Academy of Medical Sciences Initiative for Innovative Medicine","doi-asserted-by":"publisher","award":["2026-I2M-SXZX12-03"],"award-info":[{"award-number":["2026-I2M-SXZX12-03"]}],"id":[{"id":"10.13039\/501100019018","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100019018","name":"Chinese Academy of Medical Sciences Initiative for Innovative Medicine","doi-asserted-by":"publisher","award":["2025-I2M-XHXX-092"],"award-info":[{"award-number":["2025-I2M-XHXX-092"]}],"id":[{"id":"10.13039\/501100019018","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.bcp.2026.118535","type":"journal-article","created":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T15:06:50Z","timestamp":1791644810000},"page":"118535","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"P3","title":["Alnustone ameliorates atopic dermatitis by rebalancing TAp63\/\u0394Np63 to upregulate filaggrin and restore skin barrier function"],"prefix":"10.1016","volume":"254","author":[{"given":"Chunzheng","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ke","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bcp.2026.118535_b0005","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1056\/NEJMra2023911","article-title":"Atopic dermatitis","volume":"384","author":"St\u00e4nder","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bcp.2026.118535_b0010","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1093\/bjd\/ljad339","article-title":"Global epidemiology of atopic dermatitis: acomprehensive systematic analysis and modelling study","volume":"190","author":"Tian","year":"2023","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.bcp.2026.118535_b0015","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/S0140-6736(24)02519-4","article-title":"Atopic dermatitis","volume":"405","author":"Guttman-Yassky","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.bcp.2026.118535_b0020","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1111\/bjd.19580","article-title":"The global burden of atopic dermatitis: lessons from the global burden of disease study 1990-2017","volume":"184","author":"Laughter","year":"2021","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.bcp.2026.118535_b0025","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.anai.2020.08.016","article-title":"New treatments in atopic dermatitis","volume":"126","author":"Puar","year":"2021","journal-title":"Ann. Allergy Asthma Immunol."},{"key":"10.1016\/j.bcp.2026.118535_b0030","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1016\/j.jaci.2021.08.009","article-title":"JAK inhibitors in the treatment of atopic dermatitis","volume":"148","author":"Chovatiya","year":"2021","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.bcp.2026.118535_b0035","first-page":"137","article-title":"S3 guideline atopic dermatitis: part 1 - general aspects, topical and non-drug therapies, special patient groups","volume":"22","author":"Werfel","year":"2024","journal-title":"J. Dtsch. Dermatol. Ges."},{"key":"10.1016\/j.bcp.2026.118535_b0040","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/S0140-6736(15)00149-X","article-title":"Atopic dermatitis","volume":"387","author":"Weidinger","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.bcp.2026.118535_b0045","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.immuni.2015.07.007","article-title":"Barrier epithelial cells and the control of type 2 immunity","volume":"43","author":"Hammad","year":"2015","journal-title":"Immunity"},{"key":"10.1016\/j.bcp.2026.118535_b0050","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1159\/000323963","article-title":"Modifications of the innate immune system in atopic dermatitis","volume":"3","author":"Maintz","year":"2011","journal-title":"J. Innate Immun."},{"key":"10.1016\/j.bcp.2026.118535_b0055","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1016\/j.jid.2023.10.019","article-title":"Genetic and immunological pathogenesis of atopic dermatitis","volume":"144","author":"Schuler","year":"2024","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.bcp.2026.118535_b0060","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000441539","article-title":"Filaggrin and Skin Barrier Function","volume":"49","author":"Kezic","year":"2016","journal-title":"Curr. Probl. Dermatol."},{"key":"10.1016\/j.bcp.2026.118535_b0065","doi-asserted-by":"crossref","first-page":"207","DOI":"10.4168\/aair.2018.10.3.207","article-title":"Significance of skin barrier dysfunction in atopic dermatitis","volume":"10","author":"Kim","year":"2018","journal-title":"Allergy, Asthma Immunol. Res."},{"key":"10.1016\/j.bcp.2026.118535_b0070","doi-asserted-by":"crossref","first-page":"23772","DOI":"10.1016\/S0021-9258(18)35905-2","article-title":"Characterization of the human epidermal profilaggrin gene. Genomic organization and identification of an S-100-like calcium binding domain at the amino terminus","volume":"267","author":"Presland","year":"1992","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bcp.2026.118535_b0075","first-page":"5814","article-title":"Organization, structure, and polymorphisms of the human profilaggrin gene","volume":"30","author":"Gan","year":"1991","journal-title":"Biochemistry"},{"key":"10.1016\/j.bcp.2026.118535_b0080","doi-asserted-by":"crossref","first-page":"5940","DOI":"10.1021\/bi00266a033","article-title":"Characterization of a phosphorylated form of the intermediate filament-aggregating protein filaggrin","volume":"21","author":"Lonsdale-Eccles","year":"1982","journal-title":"Biochemistry"},{"key":"10.1016\/j.bcp.2026.118535_b0085","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1242\/jcs.033969","article-title":"Filaggrin in the frontline: role in skin barrier function and disease","volume":"122","author":"Sandilands","year":"2009","journal-title":"J. Cell Sci."},{"issue":"Suppl 1","key":"10.1016\/j.bcp.2026.118535_b0090","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1111\/j.1396-0296.2004.04S1005.x","article-title":"Moisturization and skin barrier function","volume":"17","author":"Rawlings","year":"2004","journal-title":"Dermatol. Ther."},{"key":"10.1016\/j.bcp.2026.118535_b0095","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1038\/ng1767","article-title":"Common loss-of-function variants of the epidermal barrier protein filaggrin are a major predisposing factor for atopic dermatitis","volume":"38","author":"Palmer","year":"2006","journal-title":"Nat. Genet."},{"key":"10.1016\/j.bcp.2026.118535_b0100","doi-asserted-by":"crossref","first-page":"R7","DOI":"10.1016\/j.jaci.2009.07.012","article-title":"Cytokine modulation of atopic dermatitis filaggrin skin expression","volume":"124","author":"Howell","year":"2009","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.bcp.2026.118535_b0105","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2021.111741","article-title":"A comprehensive review of natural products against atopic dermatitis: flavonoids, alkaloids, terpenes, glycosides and other compounds","volume":"140","author":"Wu","year":"2021","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.bcp.2026.118535_b0110","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1055\/s-2006-959730","article-title":"Three non-phenolic diarylheptanoids with anti-inflammatory activity from Curcuma xanthorrhiza","volume":"59","author":"Claeson","year":"1993","journal-title":"Planta Med."},{"key":"10.1016\/j.bcp.2026.118535_b0115","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1055\/s-2006-957867","article-title":"Non-phenolic linear diarylheptanoids from Curcuma xanthorrhiza: a novel type of topical anti-inflammatory agents: structure-activity relationship","volume":"62","author":"Claeson","year":"1996","journal-title":"Planta Med."},{"key":"10.1016\/j.bcp.2026.118535_b0120","first-page":"795","article-title":"Structural characterization and biological effects of constituents of the seeds of Alpinia katsumadai (Alpina Katsumadai seed)","volume":"7","author":"Nam","year":"2012","journal-title":"Nat. Prod. Commun."},{"key":"10.1016\/j.bcp.2026.118535_b0125","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2020.115971","article-title":"Anti-inflammatory activity of naturally occuring diarylheptanoids \u2013 a review","volume":"31","author":"Vanucci-Bacqu\u00e9","year":"2021","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.bcp.2026.118535_b0130","doi-asserted-by":"crossref","first-page":"2583","DOI":"10.1111\/bph.16377","article-title":"A natural inhibitor of diapophytoene desaturase attenuates methicillin-resistant S. aureus (MRSA) pathogenicity and overcomes drug-resistance","volume":"181","author":"Han","year":"2024","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.bcp.2026.118535_b0135","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1002\/ptr.7337","article-title":"Alnustone inhibits the growth of hepatocellular carcinoma via ROS- mediated PI3K\/Akt\/mTOR\/p70S6K axis","volume":"36","author":"Wang","year":"2022","journal-title":"Phytother. Res."},{"key":"10.1016\/j.bcp.2026.118535_b0140","doi-asserted-by":"crossref","DOI":"10.3791\/56027-v","article-title":"Isolation and culture of primary mouse keratinocytes from neonatal and adult mouse skin","author":"Li","year":"2017","journal-title":"J. Vis. Exp."},{"key":"10.1016\/j.bcp.2026.118535_b0145","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1038\/nprot.2008.50","article-title":"Isolation and short-term culture of primary keratinocytes, hair follicle populations and dermal cells from newborn mice and keratinocytes from adult mice for in vitro analysis and for grafting to immunodeficient mice","volume":"3","author":"Lichti","year":"2008","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.bcp.2026.118535_b0150","doi-asserted-by":"crossref","DOI":"10.1111\/exd.70024","article-title":"Characterisation and profiling of standard atopic dermatitis therapies in a chronic dermatitis murine model induced by oxazolone","volume":"33","author":"Calama","year":"2024","journal-title":"Exp. Dermatol."},{"key":"10.1016\/j.bcp.2026.118535_b0155","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/sj.jid.5701011","article-title":"Characterization of a hapten-induced, murine model with multiple features of atopic dermatitis: structural, immunologic, and biochemical changes following single versus multiple oxazolone challenges","volume":"128","author":"Man","year":"2008","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.bcp.2026.118535_b0160","doi-asserted-by":"crossref","DOI":"10.3390\/jcm10112506","article-title":"New treatments for atopic dermatitis targeting skin barrier repair via the regulation of FLG expression","volume":"10","author":"D\u0119bi\u0144ska","year":"2021","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.bcp.2026.118535_b0165","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41572-018-0001-z","article-title":"Atopic dermatitis","volume":"4","author":"Weidinger","year":"2018","journal-title":"Nat. Rev. Dis. Primers"},{"key":"10.1016\/j.bcp.2026.118535_b0170","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1111\/bjd.15078","article-title":"T helper (Th)1, Th17 and Th2 imbalance in mesenchymal stem cells of adult patients with atopic dermatitis: at the origin of the problem","volume":"176","author":"Orciani","year":"2017","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.bcp.2026.118535_b0175","doi-asserted-by":"crossref","first-page":"D61","DOI":"10.1093\/nar\/gkad1069","article-title":"Cistrome data browser: integrated search, analysisand visualization of chromatin data","volume":"52","author":"Taing","year":"2024","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.bcp.2026.118535_b0180","doi-asserted-by":"crossref","DOI":"10.1242\/jcs.228015","article-title":"p63-related signaling at a glance","volume":"133","author":"Fisher","year":"2020","journal-title":"J. Cell Sci."},{"key":"10.1016\/j.bcp.2026.118535_b0185","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/S1097-2765(00)80275-0","article-title":"p63, a p53 homolog at 3q27-29, encodes multiple products with transactivating, death-inducing, and dominant-negative activities","volume":"2","author":"Yang","year":"1998","journal-title":"Mol. Cell"},{"key":"10.1016\/j.bcp.2026.118535_b0190","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1038\/sj.cdd.4401914","article-title":"p53\/p63\/p73 isoforms: an orchestra of isoforms to harmonise cell differentiation and response to stress","volume":"13","author":"Murray-Zmijewski","year":"2006","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.bcp.2026.118535_b0195","doi-asserted-by":"crossref","first-page":"863","DOI":"10.15252\/embr.201439941","article-title":"Transcription factor p63 bookmarks and regulates dynamic enhancers during epidermal differentiation","volume":"16","author":"Kouwenhoven","year":"2015","journal-title":"EMBO Rep."},{"key":"10.1016\/j.bcp.2026.118535_b0200","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/S1097-2765(00)80275-0","article-title":"p63, a p53 homolog at 3q27\u201329, encodes multiple products with transactivating, death-inducing, and dominant-negative activities","volume":"2","author":"Yang","year":"1998","journal-title":"Mol. Cell"},{"key":"10.1016\/j.bcp.2026.118535_b0205","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.63266","article-title":"Dissecting the DNA binding landscape and gene regulatory network of p63 and p53","volume":"9","author":"Riege","year":"2020","journal-title":"eLife"},{"key":"10.1016\/j.bcp.2026.118535_b0210","article-title":"p63 and p53: collaborative partners or dueling rivals?","volume":"9\u20132021","author":"Woodstock","year":"2021","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.bcp.2026.118535_b0215","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1016\/j.jid.2024.08.011","article-title":"Molecular and cellular function of p63 in skin development and genetic diseases","volume":"145","author":"di Girolamo","year":"2025","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.bcp.2026.118535_b0220","doi-asserted-by":"crossref","first-page":"4544","DOI":"10.1016\/j.febslet.2006.07.004","article-title":"Derivation of the consensus DNA-binding sequence for p63 reveals unique requirements that are distinct from p53","volume":"580","author":"Ortt","year":"2006","journal-title":"FEBS Lett."},{"key":"10.1016\/j.bcp.2026.118535_b0225","doi-asserted-by":"crossref","first-page":"7363","DOI":"10.1038\/sj.onc.1210561","article-title":"p63 consensus DNA-binding site: identification, analysis and application into a p63MH algorithm","volume":"26","author":"Perez","year":"2007","journal-title":"Oncogene"},{"key":"10.1016\/j.bcp.2026.118535_b0230","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/j.molcel.2006.10.018","article-title":"Relationships between p63 binding, DNA sequence, transcription activity, and biological function in human cells","volume":"24","author":"Yang","year":"2006","journal-title":"Mol. Cell"},{"key":"10.1016\/j.bcp.2026.118535_b0235","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/s41573-021-00266-6","article-title":"Atopic dermatitis: an expanding therapeutic pipeline for a complex disease","volume":"21","author":"Bieber","year":"2022","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.bcp.2026.118535_b0240","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.jaci.2006.05.004","article-title":"Loss-of-function variations within the filaggrin gene predispose for atopic dermatitis with allergic sensitizations","volume":"118","author":"Weidinger","year":"2006","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.bcp.2026.118535_b0245","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/exd.12102","article-title":"Topical apigenin improves epidermal permeability barrier homoeostasis in normal murine skin by divergent mechanisms","volume":"22","author":"Hou","year":"2013","journal-title":"Exp. Dermatol."},{"key":"10.1016\/j.bcp.2026.118535_b0250","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1111\/j.1600-0625.2012.01455.x","article-title":"Topical hesperidin improves epidermal permeability barrier function and epidermal differentiation in normal murine skin","volume":"21","author":"Hou","year":"2012","journal-title":"Exp. Dermatol."},{"key":"10.1016\/j.bcp.2026.118535_b0255","doi-asserted-by":"crossref","DOI":"10.3390\/molecules26092626","article-title":"Effects of Aloe vera flower extract and its active constituent isoorientin on skin moisturization via regulating involucrin expression: in vitro and molecular docking studies","volume":"26","author":"Razia","year":"2021","journal-title":"Molecules"},{"key":"10.1016\/j.bcp.2026.118535_b0260","doi-asserted-by":"crossref","first-page":"11847","DOI":"10.1038\/s41598-017-10252-x","article-title":"GATA3 regulates FLG and FLG2 expression in human primary keratinocytes","volume":"7","author":"Zeitvogel","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bcp.2026.118535_b0265","doi-asserted-by":"crossref","first-page":"24105","DOI":"10.1074\/jbc.271.39.24105","article-title":"Activator protein 1 activity is involved in the regulation of the cell type-specific expression from the proximal promoter of the human profilaggrin gene","volume":"271","author":"Jang","year":"1996","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bcp.2026.118535_b0270","doi-asserted-by":"crossref","first-page":"e2931","DOI":"10.1038\/cddis.2017.322","article-title":"Aryl hydrocarbon receptor activation restores filaggrin expression via OVOL1 in atopic dermatitis","volume":"8","author":"Tsuji","year":"2017","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.bcp.2026.118535_b0275","doi-asserted-by":"crossref","first-page":"9360","DOI":"10.1128\/MCB.25.21.9360-9368.2005","article-title":"Constitutive expression of aryl hydrocarbon receptor in keratinocytes causes inflammatory skin lesions","volume":"25","author":"Tauchi","year":"2005","journal-title":"Mol. Cell Biol."},{"key":"10.1016\/j.bcp.2026.118535_b0280","doi-asserted-by":"crossref","DOI":"10.3390\/ijerph16234864","article-title":"Chloracne and hyperpigmentation caused by exposure to hazardous aryl hydrocarbon receptor ligands","volume":"16","author":"Furue","year":"2019","journal-title":"Int. J. Environ. Res. Public Health"},{"key":"10.1016\/j.bcp.2026.118535_b0285","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.jaad.2024.05.023","article-title":"Tapinarof cream 1% once daily: significant efficacy in the treatment of moderate to severe atopic dermatitis in adults and children down to 2 years of age in the pivotal phase 3 ADORING trials","volume":"91","author":"Silverberg","year":"2024","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.bcp.2026.118535_b0290","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1111\/jdv.18925","article-title":"Tapinarof for psoriasis and atopic dermatitis: 15\u2009years of clinical research","volume":"37","author":"Bissonnette","year":"2023","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"10.1016\/j.bcp.2026.118535_b0295","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1002\/iid3.427","article-title":"IL-13 modulates \u0394Np63 levels causing altered expression of barrier- and inflammation-related molecules in human keratinocytes: a possible explanation for chronicity of atopic dermatitis","volume":"9","author":"Kubo","year":"2021","journal-title":"Immun. Inflammation Dis."},{"key":"10.1016\/j.bcp.2026.118535_b0300","doi-asserted-by":"crossref","first-page":"51408","DOI":"10.1074\/jbc.M309943200","article-title":"Delta Np63 alpha expression is regulated by the phosphoinositide 3-kinase pathway","volume":"278","author":"Barbieri","year":"2003","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bcp.2026.118535_b0305","doi-asserted-by":"crossref","first-page":"2613","DOI":"10.4049\/jimmunol.2101160","article-title":"The developmental transcription factor p63 is redeployed to drive allergic skin inflammation through phosphorylation by p38\u03b1","volume":"208","author":"Jim\u00e9nez-Andrade","year":"2022","journal-title":"J. Immunol."},{"key":"10.1016\/j.bcp.2026.118535_b0310","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1038\/jid.2008.106","article-title":"Animal models of atopic dermatitis","volume":"129","author":"Jin","year":"2009","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.bcp.2026.118535_b0315","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.jdermsci.2017.12.009","article-title":"Skin wound healing in humans and mice: challenges in translational research","volume":"90","author":"Zomer","year":"2018","journal-title":"J. Dermatol. Sci."},{"key":"10.1016\/j.bcp.2026.118535_b0320","doi-asserted-by":"crossref","DOI":"10.1111\/exd.15099","article-title":"Modelling atopic dermatitis in healthy human skin for the characterization of topical compounds","volume":"33","author":"Hacini-Rachinel","year":"2024","journal-title":"Exp. Dermatol."},{"key":"10.1016\/j.bcp.2026.118535_b0325","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1177\/026119291103900508","article-title":"Hallmarks of atopic skin mimicked in vitro by means of a skin disease model based on FLG knock-down","volume":"39","author":"K\u00fcchler","year":"2011","journal-title":"Altern. Lab. Anim."},{"key":"10.1016\/j.bcp.2026.118535_b0330","doi-asserted-by":"crossref","first-page":"119","DOI":"10.3389\/fmed.2017.00119","article-title":"Atopic dermatitis studies through in vitro models","volume":"4","author":"de Vuyst","year":"2017","journal-title":"Front. Med. (Lausanne)"},{"key":"10.1016\/j.bcp.2026.118535_b0335","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.jid.2020.04.023","article-title":"Perspective and consensus opinion: good practices for using organotypic skin and epidermal equivalents in experimental dermatology research","volume":"141","author":"van den Bogaard","year":"2021","journal-title":"J. Invest. Dermatol."}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295226008774?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295226008774?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T10:56:55Z","timestamp":1791975415000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295226008774"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":67,"alternative-id":["S0006295226008774"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2026.118535","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Alnustone ameliorates atopic dermatitis by rebalancing TAp63\/\u0394Np63 to upregulate filaggrin and restore skin barrier function","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2026.118535","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"118535"}}